Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2021

View Archived Issues

Human cerebral organoids show utility to evaluate candidate inhibitors of prion accumulation in CJD

Phase III GOBI study of NOV-03 meets statistical significance on coprimary and secondary endpoints

BMC-128 shows promising antitumor activity in mouse model of melanoma

Phase II study of fostamatinib in patients with COVID-19 meets primary endpoint

FDA clears IND application for phase IIb study of AXA-1125 in NASH

Companies report progress of catumaxomab clinical trials for NMIBC

CFT-7455 shows potent tumor regression in IMiD-resistant multiple myeloma xenografts

First-in-class pan-inhibitor of KDM4 TACH-101 active in multiple cancer models

SPH Biotherapeutics presents new isolated antigen-binding proteins

New PARG inhibitors identified at Ideaya Biosciences

Accutar Biotechnology synthesizes new androgen receptor degrading PROTACs

Merck & Co. presents a novel potent, selective and brain-penetrant LRRK2 kinase inhibitor

Merck & Co. discovers KRAS G12C mutant inhibitors

BIAL Biotech discovers acid ceramidase inhibitors

BNT-162b2 and mRNA-1273 achieve only partial cross-neutralization of novel SARS-CoV-2 variants

Longeveron reports final phase I data on Lomecel-B in Alzheimer's disease

Development of human African trypanosomiasis carbazole drugs

New agonist MAb resolves chronic inflammation

New phase II trials evaluate BI-456906 in obesity and NASH

Tilt and MSD agree to study TILT-123 with Keytruda in ovarian cancer

Bispecific antibody targeting LAG-3 and PD-L1 (ABL501) for cancer immunotherapy

Iterion completes enrollment in phase I/IIa dose-expansion study of tegavivint in desmoid tumors

Moderna updates progress of COVID-19 vaccine program

Apellis reports 24-month data from phase Ib study of pegcetacoplan in geographic atrophy

Trodelvy gains accelerated approval in U.S. for advanced urothelial cancer